Diagnosticos da America SA
BOVESPA:DASA3
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.15
10.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Diagnosticos da America SA
Note Receivable
Diagnosticos da America SA
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Diagnosticos da America SA
BOVESPA:DASA3
|
Note Receivable
R$100m
|
CAGR 3-Years
19%
|
CAGR 5-Years
72%
|
CAGR 10-Years
41%
|
|
|
Fleury SA
BOVESPA:FLRY3
|
Note Receivable
R$2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
|
Note Receivable
R$8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Centro de Imagem Diagnosticos SA
BOVESPA:AALR3
|
Note Receivable
R$42.8m
|
CAGR 3-Years
34%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Diagnosticos da America SA
Glance View
Diagnósticos da América SA engages in medical diagnostics services and in the business of research and development of diagnostic tests and their application to the medical practice. The company is headquartered in Barueri, Sao Paulo. The company went IPO on 2004-11-19. The Company’s services are structured into three units: Ambulatory and Hospital, which provides clinical analyses and diagnostic imaging; Laboratory support, which provides services for small and medium-sized laboratories, and Public Health Sector, in which the Company operates through the CientificaLab brand, which focuses on providing auxiliary diagnostic support services for the public health sector. In addition, the Company is engaged in activities related to tests in food and substances to evaluate risks for the human being; import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general, and granting and administration of business franchising, including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others.
See Also
What is Diagnosticos da America SA's Note Receivable?
Note Receivable
100m
BRL
Based on the financial report for Sep 30, 2024, Diagnosticos da America SA's Note Receivable amounts to 100m BRL.
What is Diagnosticos da America SA's Note Receivable growth rate?
Note Receivable CAGR 10Y
41%
Over the last year, the Note Receivable growth was 75%. The average annual Note Receivable growth rates for Diagnosticos da America SA have been 19% over the past three years , 72% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet
